ReBOSSIS Bone Scaffold Gains FDA Clearance in Spine

ORTHOReBIRTH USA gained FDA 510(k) clearance to market ReBOSSIS® biosynthetic bone scaffold for use in posterolateral spine procedures.

The first 510(k) clearance for ReBOSSIS occurred in 2014, with an application in the pelvis and extremities. Since then, the material has surpassed the milestone of 1,500 procedures performed.


document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us